Journal
HEPATOLOGY RESEARCH
Volume 51, Issue 12, Pages 1242-1246Publisher
WILEY
DOI: 10.1111/hepr.13680
Keywords
augmented risk donor; hepatitis B; hepatitis C; liver transplantation; nucleic acid testing
Categories
Ask authors/readers for more resources
The opioid epidemic has increased organ availability for liver transplantation. Direct-acting antiviral therapy for HCV allowed acceptance of HCV viremic donor organs, while NAT led to increased detection of HCV and HBV in donors. Case studies suggest the need for more intensive and prolonged HBV screening in recipients of livers from HCV viremic donors.
The opioid epidemic has led to increased availability of organs for liver transplantation. The success of direct-acting antiviral therapy for hepatitis C (HCV) has led to the acceptance of HCV viremic donor organs. Nucleic acid testing (NAT) has led to increased detection of HCV and hepatitis B (HBV) in potential donors. A total of 36 patients underwent liver transplantation from donation after brain death donors who were HCV NAT-positive, and three of them were diagnosed with HBV several months after. All three recipients received livers from HCV viremic donors who were negative for HBV by serology and NAT. Soon after liver transplantation, HCV was treated, and all achieved sustained virologic response. They became HBV DNA-positive shortly thereafter. To date, there have been no reported cases of unexpected HBV transmission since universal donor NAT was implemented in 2013. We postulate that the inhibitory effect of HCV viremia on HBV may have prolonged the NAT window period in these donors beyond the 20-22 days quoted for solitary HBV infection. These cases highlight the need for more intensive and prolonged screening for HBV in recipients of livers from HCV viremic donors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available